SGLT2 Inhibitors, Ketones, and Cardiovascular Benefit Research Plan — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

SGLT2 Inhibitors, Ketones, and Cardiovascular Benefit Research Plan — Stella

Recruiting

Back to Type2 Diabetes trials

Early Phase 1 — Very small initial tests in humans, typically just a few people, to make sure the treatment is safe enough to study further.

Trial locations(1 site)

United States

University of Texas Health Science Center at San Antonio, San Antonio, Texas

Key details

Phase

Very early testing

Sponsor

The University of Texas Health Science Center at San Antonio

Collaborators

Doris Duke Charitable Foundation, Max and Minnie Tomerlin Voelcker Fund

Enrollment target

~30 participants

Started

January 2021

Primary completion

November 2026

Age range

18 Years – 80 Years

Last updated April 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov